Leukemia Clinical Trials in Boston

Showing 161-180 of 694 trials

Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML

NCT02091245

This research study involves participants who have acute lymphoblastic or acute myelogenous leukemia that has relapsed or has become resistant (or refractory) to standard therapies. This research study is evaluating a drug called KPT-330. Laboratory and other studies suggest that the study drug, KPT-330, may prevent leukemia cells from growing and may lead to the destruction of leukemia cells. It is thought that KPT-330 activates cellular processes that increase the death of leukemia cells. The main goal of this study is to evaluate the side effects of KPT-330 when it is administered to children and adolescents with relapsed or refractory leukemia.

Relapsed Acute Lymphoblastic Leukemia (ALL)Refractory Acute Lymphoblastic Leukemia (ALL)Relapsed Acute Myelogenous Leukemia (AML)+6 more

Dana-Farber Cancer Institute16 participantsStarted Mar 2014

San Francisco, California, United States • Aurora, Colorado, United States • Atlanta, Georgia, United States +7 more locations

ACTIVE_NOT_RECRUITINGPHASE1< 1 mile

Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALL

NCT03740334

This research study is evaluating a drug called ribociclib (LEE011) given in combination with everolimus and other standard of care chemotherapy drugs as a possible treatment for relapsed or refractory ALL. The names of the drugs involved in this study are: * ribociclib * everolimus * dexamethasone

Acute Lymphoblastic Leukemia ALL

Dana-Farber Cancer Institute45 participantsStarted Jan 2019

Aurora, Colorado, United States • Wilmington, Delaware, United States • Atlanta, Georgia, United States +9 more locations

Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML

Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALL

Leukemia Trials in Other Cities

A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors

An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer

Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors

Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors

A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)

Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study

Biology of Young Lung Cancer Study: The YOUNG LUNG Study

A Study of XMT-1660 in Participants With Solid Tumors

Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

The Myelin Disorders Biorepository Project

A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS

Study of AVZO-021 in Patients With Advanced Solid Tumors

Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression

Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.

A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy

Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia

Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer

Other Conditions in Boston